345 related articles for article (PubMed ID: 28924284)
1. Molecular biology of glioblastoma: Classification and mutational locations.
Soomro SH; Ting LR; Qing YY; Ren M
J Pak Med Assoc; 2017 Sep; 67(9):1410-1414. PubMed ID: 28924284
[TBL] [Abstract][Full Text] [Related]
2. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
4. Genetic pathways to primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Am J Pathol; 2007 May; 170(5):1445-53. PubMed ID: 17456751
[TBL] [Abstract][Full Text] [Related]
5. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity analysis in malignant gliomas.
Mizoguchi M; Kuga D; Guan Y; Hata N; Nakamizo A; Yoshimoto K; Sasaki T
Brain Tumor Pathol; 2011 Jul; 28(3):191-6. PubMed ID: 21629980
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report.
Joo M; Park SH; Chang SH; Kim H; Choi CY; Lee CH; Lee BH; Hwang YJ
Hum Pathol; 2013 Feb; 44(2):282-8. PubMed ID: 23058249
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
10. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
11. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
[TBL] [Abstract][Full Text] [Related]
12. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
[TBL] [Abstract][Full Text] [Related]
13. Genetic pathways to glioblastoma: a population-based study.
Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
[TBL] [Abstract][Full Text] [Related]
14. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.
Martinez R; Schackert HK; von Kannen S; Lichter P; Joos S; Schackert G
Brain Pathol; 2003 Oct; 13(4):598-607. PubMed ID: 14655763
[TBL] [Abstract][Full Text] [Related]
15. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
16. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
17. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
18. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
20. Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies.
Castells X; Acebes JJ; Majós C; Boluda S; Julià-Sapé M; Candiota AP; Ariño J; Barceló A; Arús C
Br J Cancer; 2012 May; 106(11):1816-25. PubMed ID: 22568967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]